Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01189903
Recruitment Status : Unknown
Verified January 2014 by National University Hospital, Singapore. Recruitment status was: Active, not recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
21 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically or cytologically proven metastatic colorectal adenocarcinoma that is refractory to standard therapy and not amenable to surgery with curative intent.
At least one lesion that is suitable for a repeated biopsy; eg. subcutaneous nodule, skin lesion, rectal tumor, colonic mass easily reached by colonoscopy, peritoneal masses at least 3cm in maximum diameter that are easily assessable by image guided core biopsy.
For liver lesions, more superficially located lesions at least 3cm in maximum dimension with a rim of normal liver tissue, assessable safely by image guided core biopsy as determined by an experienced interventional radiologist.
Eastern Cooperative Oncology Group ECOG performance status of 0 or 1 (see Appendix 10.4).
Adequate bone marrow function (absolute neutrophil count =1,500/mm3; platelet count =100000/mm3; hemoglobin =9g/dl
Adequate liver and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment:
Total bilirubin < 1.5 x the upper limit of normal (ULN).
Alanine transaminase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (< 5 x ULN for patients with liver involvement of their cancer).
Amylase and lipase < 1.5 x the ULN
Serum creatinine < 1.5 x the ULN.
Glomerular filtration rate (GFR) = 30 ml/min/1.73 m2 according to the MDRD (Modified diet in renal disease) abbreviated formula
Prothrombin time, international normalized ratio (INR) and partial thromboplastin time less than or equal to 1.2 times the ULN.
Male or female at least 21 years of age.
A female subject is eligible to enter and participate in the study if she is:
Non-childbearing potential (ie. physiologically incapable of becoming pregnant) including any women who:
Has had a hysterectomy or
Has bilateral oophorectomy (ovariectomy) or
Has bilateral tubal ligation or
Is postmenopausal (demonstrate total cessation of menses for greater than or
Childbearing potential, has a negative serum or urine pregnancy test at screening, agrees to one of the following: double barrier contraception or abstinence.
Predicted life expectancy of at least 12 weeks.
Resting oxygen saturation greater than 92% on room air.
Written informed consent.
Able to swallow and retain oral medication.
Prothrombin time (PT), International Normalized Ratio for PT (PT INR), and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) within normal limits.